Radiolabeled Anti-Claudin 4 and Anti-Prostate Stem Cell Antigen: Initial Imaging in Experimental Models of Pancreatic Cancer
Authors:
Open Access
- 1 March 2007
- journal article
- Published by SAGE Publications in Molecular Imaging
- Vol. 6 (2) , 131-9
Abstract
Global expression profiling of pancreatic cancers has identified two cell surface molecules, claudin 4 and prostate stem cell antigen (PSCA), as being overexpressed in the vast majority of cases. Two antibodies, anti-claudin 4 and anti-PSCA, were radiolabeled with iodine 125 (125I) for imaging pancreatic cancer xenografts in mice using gamma scintigraphy and single-photon emission computed tomography-computed tomography (SPECT-CT). Immunofluorescence staining of intact and permeabilized Colo357 human pancreatic cancer cells showed strong extracellular staining by both anti-PSCA and anti-claudin 4. Biodistribution studies in claudin 4 and PSCA-expressing Colo357 and PANC-1 subcutaneous xenograft models in mice showed that [125I]anti-claudin 4 tumor to muscle ratio uptake was 4.3 in Colo357 at 6 days postinjection and 6.3 in PANC-1 xenografts at 4 days postinjection. Biodistribution of [125I]anti-PSCA showed tumor to muscle ratio uptake of 4.9 in Colo357 at 6 days postinjection. Planar gamma scintigraphic imaging in Colo357 xenograft-bearing mice showed clear tumor uptake of [125I]anti-claudin 4 by 24 hours postinjection and by 48 hours postinjection for [125I]anti-PSCA. SPECT-CT imaging with [125I]anti-claudin 4 and [125I]anti-PSCA in an L3.6PL orthotopic xenograft model showed strong tumor and spleen uptake at 5 days postinjection. Both anti-claudin 4 and anti-PSCA demonstrate promise as radiodiagnostic and possibly radiotherapeutic agents for human pancreatic cancers.Keywords
This publication has 23 references indexed in Scilit:
- Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic CancerPancreas, 2005
- Impact of Reconstruction Methods on Outcome of Pancreatoduodenectomy in Pancreatic Cancer PatientsWorld Journal of Surgery, 2005
- Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 DiabodyCancer Research, 2005
- Improved Targeting of Pancreatic CancerClinical Cancer Research, 2004
- Claudin 4 Protein Expression in Primary and Metastatic Pancreatic CancerAmerican Journal of Clinical Pathology, 2004
- Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosisInternational Journal of Cancer, 2003
- Novel Bioactive and Stable Neurotensin Peptide Analogues Capable of Delivering Radiopharmaceuticals and Molecular Beacons to TumorsJournal of Medicinal Chemistry, 2003
- Evidence-Based Pancreatic Head Resection for Pancreatic Cancer and Chronic PancreatitisAnnals of Surgery, 2002
- Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancerOncogene, 2000
- Perihilar Cholangiocarcinoma Postoperative Radiotherapy Does Not Improve SurvivalAnnals of Surgery, 1995